Individual Study / BQC19

Biobanque Québécoise de la COVID-19
  1. Home
  2. Individual Studies
  3. BQC19

Biobanque Québécoise de la COVID-19

BQC19 logo
Networks -
Datasets -
Variables -
Start Year
2020
Supplementary Information
Visit BQC19
Add to cart

Members

Download
Investigators Contacts
  • Dr. Simon Rousseau
    McGill Health University
  • Dr. Madeleine Durand
    Université de Montréal
  • Julie Bérubé
    MUHC - McGill University Health Centre
  • Dr. Simon Rousseau
    McGill Health University
  • Dr. Madeleine Durand
    Université de Montréal

Design

Study design
Case-control
Follow Up

After first hospitalization, inpatients (positive and control cases) are followed-up at 7 days post hospitalization. Starting June 2020, inpatients are followed-up at 14 and 30 days post hospitalization. Inpatients are also followed-up at 30, 90, 180, 365, 540 and 730 days post hospitalization discharge.

Outpatients are not followed in the acute phase of COVID (0-14 days), follow-ups begin approximately 30 days following the date of the diagnostic test by PCR tests (or other). They are also followed-up 90, 180, 365, 540 and 730 days post a SARS-CoV-2 positive test result.

Some sites have continued to follow up on their own research funds and these follow-ups are entered into the BQC19 databases.

Follow-up dates are approximate and follow-up visits may be done consecutively for pediatric patients (since there were differences in the hospitalizations of the pediatric cases, it is possible that the 5 visits were also consecutive days).

For inpatients and outpatients, starting February 2023, the follow-ups at 365 and 730 days is spread over 5 sites only.

Supplementary Information

Marker Paper

Tremblay K, Rousseau S, Zawati MH, et al. The Biobanque québécoise de la COVID-19 (BQC19)-A cohort to prospectively study the clinical and biological determinants of COVID-19 clinical trajectories. PLoS One. 2021 May 19;16(5):e0245031. doi: 10.1371/journal.pone.0245031.

PUBMED 34010280

Recruitment

Recruitment Target
  • Individuals

Number of Participants

Number of Participants
6,273
Number of Participants with Biological Samples
5,263
Supplementary Information
* As of August 2023, 6273 participants (including 83 pregnant women) have been enrolled. * 3 inpatient participants have an inderteminate diagnosis for COVID-19 or still have there information entry in progress. * 2 outpatient participants have an inderteminate diagnosis for COVID-19 or still have there information entry in progress.

Access

Availability of data and biosamples

Possible Access to Data
Possible Access to Biosamples
Other
Yes
No
Not applicable
Don't know

Timeline

Populations

Selection Criteria
Newborns
Twins
Countries
  • Canada
Ethnic Origin
Health Status
  • Participants are included if they were hospitalized with a moderate or severe illness and who underwent a PCR test for SARS-CoV-2 with a positive result.
Other Criteria
Inclusion criteria for adults and children: * Patients who were tested for COVID-19 at one of the participating institutions of the BQC19. Inclusion criteria for adults only: * Adults capable of consent to research. * Adults rendered incapable of consent to research due to COVID-19 (sudden and temporary incapacity), if represented by an agent, guardian or curator. * Adults incapable of consent to research due to a condition other than COVID-19, if represented by an agent, guardian or curator.
Supplementary Information about selection criteria

Recruitment

Sources of recruitment
  • Specific population
Specific Population
  • Clinic patients
Supplementary Information
Participants are recruited during a hospital stay in a COVID unit or in intensive care. Recruitement of adult patients ended on February 14th 2023.

Number of Participants

Number of Participants
2,541
Number of Participants with Biological Samples
2,541
Data Collection Events
# Name Description Start End
0 BCQ19 - Inpatient positive cases - Enrollment Demographic information, patient type and profile (COVID status, severe/mild disease, age, sex, weight, height, smoking status, drug use, healthcare worker status, etc.), medical history, results ... 2020-04
1 BCQ19 - Inpatient positive cases - 2 days post hospitalization Information on description of the visit and the sampling carried out for the BQC19, including a calculation of the time elapsed between the visit and the recruitment, and between the visit and the ... 2020-04 2023-02
2 BCQ19 - Inpatient positive cases - 7 days post hospitalization Information on description of the visit and the sampling carried out for the BQC19, including a calculation of the time elapsed between the visit and the recruitment, and between the visit and the ... 2020-04 2023-02
3 BCQ19 - Inpatient positive cases - 14 days post hospitalization Information on description of the visit and the sampling carried out for the BQC19, including a calculation of the time elapsed between the visit and the recruitment, and between the visit and the ... 2020-06 2023-02
4 BCQ19 - Inpatient positive cases - 30 days post hospitalization Information on description of the visit and the sampling carried out for the BQC19, including a calculation of the time elapsed between the visit and the recruitment, and between the visit and the ... 2020-06 2023-02
5 BCQ19 - Inpatient positive cases - Discharge Hospital stay summary information including time in emergency, admission to hospital and length of hospitalization, admission to intensive care with length of stay, transfer from one institution ... 2020-04 2023-02
6 BCQ19 - Inpatient positive cases - 30 days post discharge Description of the visit and the sampling carried out for the BQC19, including a calculation of the time elapsed between the visit and the recruitment, and between the visit and the manifestation ... 2020-05 2023-02
7 BCQ19 - Inpatient positive cases - 90 days post discharge Description of the visit and the sampling carried out for the BQC19, including a calculation of the time elapsed between the visit and the recruitment, and between the visit and the manifestation ... 2020-07 2023-02
8 BCQ19 - Inpatient positive cases - 180 days post discharge Description of the visit and the sampling carried out for the BQC19, including a calculation of the time elapsed between the visit and the recruitment, and between the visit and the manifestation ... 2020-08 2023-02
9 BCQ19 - Inpatient positive cases - 365 days post discharge Description of the visit and the sampling carried out for the BQC19, including a calculation of the time elapsed between the visit and the recruitment, and between the visit and the manifestation ... 2021-02
10 BCQ19 - Inpatient positive cases - 540 days post discharge Description of the visit and the sampling carried out for the BQC19, including a calculation of the time elapsed between the visit and the recruitment, and between the visit and the manifestation ... 2021-08 2023-02
11 BCQ19 - Inpatient positive cases - 730 days post discharge Information on the type of vaccine received (Pfizer, Moderna, AstraZeneca, other), the number of doses received and side effects are collected through a questionnaire. 2022-02
Selection Criteria
Newborns
Twins
Countries
  • Canada
Ethnic Origin
Health Status
  • Participants are included if they were hospitalized with a moderate or severe illness and who underwent a PCR test for SARS-CoV-2 with a negative result.
Other Criteria
Inclusion criteria for adults and children: * Patients who were tested for COVID-19 at one of the participating institutions of the BQC19. Inclusion criteria for adults only: * Adults capable of consent to research. * Adults rendered incapable of consent to research due to COVID-19 (sudden and temporary incapacity), if represented by an agent, guardian or curator. * Adults incapable of consent to research due to a condition other than COVID-19, if represented by an agent, guardian or curator.
Supplementary Information about selection criteria
Recruitement of adult patients ended on February 14th 2023.

Recruitment

Sources of recruitment
  • Specific population
Specific Population
  • Clinic patients
Supplementary Information
Participants are recruited during a hospital stay in a COVID unit or in intensive care. Recruitement of adult patients ended on February 14th 2023.

Number of Participants

Number of Participants
911
Number of Participants with Biological Samples
911
Supplementary Information about selection criteria
Data Collection Events
# Name Description Start End
0 BCQ19 - Inpatient controls - Enrollment Demographic information, patient type and profile (COVID status, severe/mild disease, age, sex, weight, height, smoking status, drug use, healthcare worker status, etc.), medical history, results ... 2020-05
1 BCQ19 - Inpatient controls - 2 days post hospitalization Information on description of the visit and the sampling carried out for the BQC19, including a calculation of the time elapsed between the visit and the recruitment, and between the visit and the ... 2020-05 2023-02
2 BCQ19 - Inpatient controls - 7 days post hospitalization Information on description of the visit and the sampling carried out for the BQC19, including a calculation of the time elapsed between the visit and the recruitment, and between the visit and the ... 2020-05 2023-02
3 BCQ19 - Inpatient controls - 14 days post hospitalization Information on description of the visit and the sampling carried out for the BQC19, including a calculation of the time elapsed between the visit and the recruitment, and between the visit and the ... 2020-06 2023-02
4 BCQ19 - Inpatient controls - 30 days post hospitalization Information on description of the visit and the sampling carried out for the BQC19, including a calculation of the time elapsed between the visit and the recruitment, and between the visit and the ... 2020-06 2023-02
5 BCQ19 - Inpatient controls - Discharge Hospital stay summary information including time in emergency, admission to hospital and length of hospitalization, admission to intensive care with length of stay, transfer from one institution ... 2020-05
6 BCQ19 - Inpatient controls - 30 days post discharge Description of the visit and the sampling carried out for the BQC19, including a calculation of the time elapsed between the visit and the recruitment, and between the visit and the manifestation ... 2020-05 2023-02
7 BCQ19 - Inpatient controls - 90 days post discharge Description of the visit and the sampling carried out for the BQC19, including a calculation of the time elapsed between the visit and the recruitment, and between the visit and the manifestation ... 2020-07 2023-02
8 BCQ19 - Inpatient controls - 180 days post discharge Description of the visit and the sampling carried out for the BQC19, including a calculation of the time elapsed between the visit and the recruitment, and between the visit and the manifestation ... 2020-08 2023-02
9 BCQ19 - Inpatient controls - 365 days post discharge Description of the visit and the sampling carried out for the BQC19, including a calculation of the time elapsed between the visit and the recruitment, and between the visit and the manifestation ... 2021-01
10 BCQ19 - Inpatient controls - 540 days post discharge Description of the visit and the sampling carried out for the BQC19, including a calculation of the time elapsed between the visit and the recruitment, and between the visit and the manifestation ... 2021-08 2023-02
11 BCQ19 - Inpatient controls - 730 days post discharge Information on the type of vaccine received (Pfizer, Moderna, AstraZeneca, other), the number of doses received and side effects are collected through a questionnaire. 2022-03
Selection Criteria
Minimum age
18
Newborns
Twins
Countries
  • Canada
Ethnic Origin
Health Status
  • Participants with asymptomatic and mild symptoms who underwent a PCR test for SARS-CoV-2 with a positive result are included.
Other Criteria
Inclusion: * Patients who were tested for COVID-19 at one of the participating institutions of the BQC19. * Adults capable of consent to research. * Adults rendered incapable of consent to research due to COVID-19 (sudden and temporary incapacity), if represented by an agent, guardian or curator. * Adults incapable of consent to research due to a condition other than COVID-19, if represented by an agent, guardian or curator. Due to a decrease in PCR screenings, the study stopped requesting for mandatory PCR test since November 2022.
Supplementary Information about selection criteria

Recruitment

Sources of recruitment
  • Specific population
Specific Population
  • Clinic patients
Supplementary Information
Participants are recruited in outpatient clinics or post-COVID clinics. Recruitement ended on February 14th 2023.

Number of Participants

Number of Participants
2,638
Number of Participants with Biological Samples
2,638
Data Collection Events
# Name Description Start End
0 BCQ19 - Outpatient positive cases - Enrollment Patient type and profile information such as COVID status, severe or mild illness, age, sex, weight, height, smoking status, drug use, including whether the individual is a health care worker, ... 2020-04 2023-02
2 BCQ19 - Outpatient positive cases - 30 days post diagnosis Description of the visit and the sampling carried out for the BQC19, including a calculation of the time elapsed between the visit and the recruitment, and between the visit and the manifestation ... 2020-05 2023-02
3 BCQ19 - Outpatient positive cases - 90 days post diagnosis Description of the visit and the sampling carried out for the BQC19, including a calculation of the time elapsed between the visit and the recruitment, and between the visit and the manifestation ... 2020-07 2023-02
4 BCQ19 - Outpatient positive cases - 180 days post diagnosis Description of the visit and the sampling carried out for the BQC19, including a calculation of the time elapsed between the visit and the recruitment, and between the visit and the manifestation ... 2020-08 2023-02
5 BCQ19 - Outpatient positive cases - 365 days post diagnosis Description of the visit and the sampling carried out for the BQC19, including a calculation of the time elapsed between the visit and the recruitment, and between the visit and the manifestation ... 2021-03
6 BCQ19 - Outpatient positive cases - 540 days post diagnosis Description of the visit and the sampling carried out for the BQC19, including a calculation of the time elapsed between the visit and the recruitment, and between the visit and the manifestation ... 2021-08 2023-02
7 BCQ19 - Outpatient positive cases - 730 days post diagnosis Information on the type of vaccine received (Pfizer, Moderna, AstraZeneca, other), the number of doses received and side effects are collected through a questionnaire. 2022-03
Selection Criteria
Minimum age
18
Newborns
Twins
Countries
  • Canada
Ethnic Origin
Health Status
  • Participants with asymptomatic and mild symptoms who underwent a PCR test for SARS-CoV-2 with a negative result are included.
Other Criteria
Inclusion: * Patients who were tested for COVID-19 at one of the participating institutions of the BQC19. * Adults capable of consent to research. * Adults rendered incapable of consent to research due to COVID-19 (sudden and temporary incapacity), if represented by an agent, guardian or curator. * Adults incapable of consent to research due to a condition other than COVID-19, if represented by an agent, guardian or curator. Due to a decrease in PCR screenings, the study stopped requesting for mandatory PCR test since November 2022.
Supplementary Information about selection criteria

Recruitment

Sources of recruitment
  • Specific population
Specific Population
  • Clinic patients
Supplementary Information
Participants are recruited in outpatient clinics or post-COVID clinics. Recruitement ended on February 14th 2023.

Number of Participants

Number of Participants
136
Number of Participants with Biological Samples
136
Supplementary Information about selection criteria
Data Collection Events
# Name Description Start End
0 BCQ19 - Outpatient controls - Enrollment Patient type and profile information such as COVID status, severe or mild illness, age, sex, weight, height, smoking status, drug use, including whether the individual is a health care worker, ... 2020-03 2023-02
2 BCQ19 - Outpatient controls - 30 days post diagnosis Description of the visit and the sampling carried out for the BQC19, including a calculation of the time elapsed between the visit and the recruitment, and between the visit and the manifestation ... 2020-05 2023-02
3 BCQ19 - Outpatient controls - 90 days post diagnosis Description of the visit and the sampling carried out for the BQC19, including a calculation of the time elapsed between the visit and the recruitment, and between the visit and the manifestation ... 2020-07 2023-02
4 BCQ19 - Outpatient controls - 180 days post diagnosis Description of the visit and the sampling carried out for the BQC19, including a calculation of the time elapsed between the visit and the recruitment, and between the visit and the manifestation ... 2020-08 2023-02
5 BCQ19 - Outpatient controls - 365 days post diagnosis escription of the visit and the sampling carried out for the BQC19, including a calculation of the time elapsed between the visit and the recruitment, and between the visit and the manifestation ... 2021-03
6 BCQ19 - Outpatient controls - 540 days post diagnosis escription of the visit and the sampling carried out for the BQC19, including a calculation of the time elapsed between the visit and the recruitment, and between the visit and the manifestation ... 2021-08 2023-02
7 BCQ19 - Outpatient controls - 730 days post diagnosis Information on the type of vaccine received (Pfizer, Moderna, AstraZeneca, other), the number of doses received and side effects are collected through a questionnaire. 2022-03

Classifications

Socio-demographic and economic characteristics
Lifestyle and behaviours
Birth, pregnancy and reproductive health history
Perception of health, quality of life, development and functional limitations
Diseases
Symptoms and signs
Medication and supplements
Non-pharmacological interventions
Health and community care services utilization
Death
Physical measures and assessments
Laboratory measures
Cognition, personality and psychological measures and assessments
Life events, life plans, beliefs and values
Preschool, school and work life
Social environment and relationships
Physical environment
Administrative information
Perception of health
Quality of life
Life course development
Functional limitations
Other perception of health, quality of life and functional limitation-related information

Socio-demographic and economic characteristics

Age/birthdate
Sex/gender
Family and household structure
Residence
Birthplace
Labour force and retirement

Lifestyle and behaviours

Tobacco
Drugs

Birth, pregnancy and reproductive health history

Pregnancy, delivery and birth

Perception of health, quality of life, development and functional limitations

Perception of health
Functional limitations

Diseases

Certain infectious and parasitic diseases (A00-B99)
Neoplasms (C00-D48)
Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism (D50-D89)
Endocrine, nutritional and metabolic diseases (E00-E90)
Mental and behavioural disorders (F00-F99)
Diseases of the nervous system (G00-G99)
Diseases of the eye and adnexa (H00-H59)
Diseases of the ear and mastoid process (H60-H95)
Diseases of the circulatory system (I00-I99)
Diseases of the respiratory system (J00-J99)
Diseases of the digestive system (K00-K93)
Diseases of the musculoskeletal system and connective tissue (M00-M99)
Diseases of the genitourinary system (N00-N99)
Congenital malformations, deformations and chromosomal abnormalities (Q00-Q99)
External causes of morbidity and mortality (V01-Y98)
Diseases without precise specification or falling into multiple categories

Symptoms and signs

Symptoms and signs involving the circulatory and respiratory systems (R00-R09)
Symptoms and signs involving the digestive system and abdomen (R10-R19)
Symptoms and signs involving the skin and subcutaneous tissue (R20-R23)
Symptoms and signs involving nervous and musculoskeletal systems (R25-R29)
Symptoms and signs involving cognition, perception, emotional state and behaviour (R40-R46)
Symptoms and signs involving speech and voice (R47-R49)
General symptoms and signs (R50-R69)
Symptoms related to multiple categories

Medication and supplements

Medication and supplement intake

Non-pharmacological interventions

Radiological interventions
Laboratory diagnosis interventions
Other and unspecified non-pharmacological interventions

Health and community care services utilization

Visits to health professionals
Hospitalizations

Death

Vital status
Cause of death

Physical measures and assessments

Anthropometry
Circulation and respiration
Other physical measures and assessments

Laboratory measures

Hematology
Biochemistry
Virology
Immunology

Physical environment

Biological exposure

Administrative information

Identifiers
Date and time-related information
Questionnaire and interview-related information
Physical and cognitive measure and biosample-related information
Other administrative information

Functional limitations

Activities of Daily Living